In the treatment of Alzheimer’s disease (AD), health care professionals are in dire need of clinical confidence in the evidence-based potential of novel disease-modifying therapeutic options. Several promising classes of emerging agents such as amyloid-targeting humanized monoclonal antibodies (mAbs), incretin-based therapies, and others are poised to shift the paradigm of diagnosis, management, and treatment of MCI and early dementia in AD. These emerging therapies require that clinicians and multidisciplinary teams be up to date on safety, efficacy, and mechanisms of action to optimize standards of care for patients with AD.
In the third activity of this three-part CME Outfitters Snack series, expert faculty will guide learners through identifying the latest data on safety, efficacy, and mechanisms of current and emerging disease-modifying therapeutic options for the management of AD.
At the conclusion of this activity, learners will be able to better:
Supported by an educational grant from Novo Nordisk, Inc.
Primary Audience: Physicians, nurse practitioners (NPs), and physician associates (PAs) in the neurology, geriatric, and psychiatry settings
Secondary audience: PCPs and supporting HCPs who evaluate or refer patients with MCI or manage patients with AD
In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education Credit for learning and change.
CME Outfitters, LLC, designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is designated for 0.50 contact hours.
California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.
This application-based activity is approved for 0.50 contact hours (0.05 CEUs) of continuing pharmacy credit (JA0007185-0000-24-033-H01-P).
CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid until 05/28/2025. PAs should only claim credit commensurate with the extent of their participation.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Dr. Atri reports the following financial relationships:
Advisory Board: Eisai Inc.; Lundbeck; Merck & Co., Inc.; Novo Nordisk; and Roche/Genentech, Inc.
Consultant: Eisai Inc.; Lundbeck; Merck & Co., Inc.; Novo Nordisk; Prothena; and Roche/Genentech, Inc.
Grants: (Institutional research grant/contract funding): Arizona Department of Health Services; Foundation for National Institutes of Health (FNIH); Gates Ventures; National Institute on Aging (NIA/NIH; and Washington University St. Louis (as Project Arm Leader for DIAN-TU)
Research Support (Institutional research support or grants for observational or biomarker studies or clinical trials): Alzheimer’s Disease Consortia – Coordinating research institutes or government funding (Alzheimer’s Clinical Trials Consortium (ACTC); Alzheimer’s Disease Cooperative Study (ADCS); Alzheimer’s Therapeutic Research Institute; (ATRI); National Institutes of Health (NIH); Athira Pharma, Inc.; Alzheon, Inc.; Biohaven (with ADCS); Eisai Inc. (with ATRI/ACTC); Global Alzheimer’s Platform Foundation; Indiana University (observational cohort); Johns Hopkins (clinical trial); Lilly (with ACTC/NIH); PEACE-AD Study (with ADCS); Vivoryon (with ADCS)
Dr. Cohen reports the following financial relationships:
Advisory Board (paid to institution only): Biogen; Cognivue, Inc.; Cogstate; Eisai Inc.; Lilly; Novartis Pharmaceuticals Corporation; Novo Nordisk; Roche; and SciNeuro Pharmaceuticals
Consultant (no personal fees): Alnylam Pharmaceuticals, Inc.; Biogen; Biohaven; Bristol Myers Squibb Company; Cassava Sciences, Inc.; Cognivue, Inc.; Cogstate; Eisai Inc.; Lilly; INmuneBio; Lundbeck; Novartis Pharmaceuticals Corporation; Novo Nordisk; Parexel; RetiSpec Inc.; and Roche
Research Grants (paid to institution only): AbbVie Inc.; AgeneBio, Inc.; Alector, Inc.; Alnylam Pharmaceuticals, Inc.; Alzheon, Inc.; Anavex; Biogen; Cassava Sciences, Inc.; Eisai Inc.; Lilly; GAP; GSK; INmuneBio; Janssen Pharmaceuticals, Inc.; Novo Nordisk; RetiSpec Inc.; Roche; and UCB, Inc.
The following individuals have no financial relationships to disclose:
Rebecca Vargas-Jackson, MD (Peer Reviewer)
Michael Franks, APRN, AGACNP-BC, FNP-BC (Peer Reviewer)
Keshia Pitt, PhD (Planning Committee)
Erin Spencer, PharmD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (70% pass rate required). This website supports all browsers except Internet Explorer for Mac.
Call us at 877.CME.PROS (877.263.7767).
SN-234-052824-68
